Lee D W, Teoh D C, Chong F L
Likas Hospital, Oncology and Radiotherapy Department, Karung Berkunci No 187, Kota Kinabalu, Sabah 88996, Malaysia.
Rafflesia Medical Centre, Kota Kinabalu, Sabah, Malaysia.
Med J Malaysia. 2016 Dec;71(6):348-350.
There are many options in the treatment of heavily pretreated metastatic breast cancer however none of the therapeutic agents have shown promising improvement of survival with good toxicity profile. Eribulin is a novel nontaxane microtubule dynamics inhibitor. Two recent clinical trial showed that Eribulin improves progression-free and overall survival in this subset of patients. We report our experience with using Eribulin in five patients with metastatic breast cancer either in second or third-line setting, in our centre.
在治疗经过大量预处理的转移性乳腺癌方面有很多选择，然而，没有一种治疗药物在毒性特征良好的情况下显示出有望提高生存率。艾瑞布林是一种新型的非紫杉烷类微管动力学抑制剂。最近的两项临床试验表明，艾瑞布林可改善这类患者亚组的无进展生存期和总生存期。我们报告了我们中心在二线或三线治疗中使用艾瑞布林治疗五例转移性乳腺癌患者的经验。
